Table 1 Association between LBCS expression and clinicopathological features of prostate cancer from Cohort 1
From: A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
Characteristics | Cases (%) | χ 2 | P-value | |
|---|---|---|---|---|
Total Cohort 1 Patients (N) | 130 | Â | Â | |
Patients with complete clinical and follow up information (N) | 130 | Â | Â | |
LBCS expression | Low | High | Â | Â |
Age (Year) | ||||
 ≤70 | 30 (23) | 39 (30) | 2.502 | 0.114 |
 >70 | 35 (27) | 26 (20) | ||
Gleason Score | ||||
 6–7 | 27 (21) | 50 (38) | 16.851 | 0.000* |
 8–10 | 38 (29) | 15 (12) | ||
Tumor stage | ||||
 T1–2 | 27 (21) | 52 (40) | 20.166 | 0.000* |
 T3–4 | 38 (29) | 13 (10) | ||
Lymphnodes status N | ||||
 Negative | 50 (38) | 58 (45) | 3.502 | 0.061 |
 Positive | 15 (12) | 7 (5) | ||
Distant Metastasis M | ||||
 M0 | 55 (24) | 59 (33) | 1.140 | 0.286 |
 M1 | 10 (25) | 6 (18) | ||